Search Within

Mark Kris

Formats
  1. Journal Article (478)
  2. Meeting Abstract (355)
  3. Conference Paper (16)
  4. Book Section (9)
  5. Review (6)
  6. Guidelines (2)
  7. Editorial (1)
  8. Miscellaneous (1)
  9. Research Letter (1)
Groups
  1. Department of Medicine (869)
  2. Solid Tumor Oncology Division (869)
  3. Thoracic Oncology (869)
  4. Department of Pathology and Laboratory Medicine (317)
  5. GSK Faculty (290)
  6. Human Oncology and Pathogenesis Program (223)

More Groups

People
  1. Gregory Riely (220)
  2. Marc Ladanyi (189)
  3. Vincent Miller (172)
  4. Valerie Rusch (130)
  5. Maria Arcila (123)
  6. Jamie Chaft (107)

More People

Years
  1. 2025 (4)
  2. 2024 (18)
  3. 2023 (27)
  4. 2022 (21)
  5. 2021 (21)
  6. 2020 (25)

More Years

Publications
  1. Journal of Clinical Oncology (234)
  2. Journal of Thoracic Oncology (131)
  3. Clinical Cancer Research (65)
  4. Cancer (33)
  5. Lung Cancer (31)
  6. Annals of Oncology (24)

More Publications

Publishers
  1. American Society of Clinical Oncology (252)
  2. Elsevier Inc. (179)
  3. American Association for Cancer Research (105)
  4. Oxford University Press (47)
  5. Wiley Blackwell (36)
  6. Elsevier Ireland Ltd. (30)

More Publishers

Results (869)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) in patients (PTS) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIS)
    Meeting Abstract

    Yu, H. A.; Johnson, M. L.; Urman, A.; Rademaker, A.; Hart, E.; Weitner, B. B.; Patel, J. D.; Kris, M.; Riely, G.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Comparison of the characteristics and clinical course of patients with metastatic KRAS mutant lung cancers
    Meeting Abstract

    Riely, G.; Yu, H. A.; Sima, C. S.; Shen, R. L.; Kass, S. L.; Kris, M. G.; Ladanyi, M.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis Program at Memorial Sloan-Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Pietanza, M. C.; Varghese, A.; Won, H.; Rekhtman, N.; Wang, L.; Travis, W. D.; Paik, P. K.; Riely, G. J.; Zakowski, M. F.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • A phase II trial of paclitaxel, pemetrexed and bevacizumab in patients with untreated, advanced lung cancers
    Meeting Abstract

    Pietanza, M. C.; Hellmann, M. D.; Rizvi, N.; Azzoli, C. G.; Smith-Marrone, S.; Fiore, J.; Tyson, L. B.; Sumner, D. K.; Hergianto, A. B.; Kass, S. L.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Patterns of metastasis and survival in patients with PI3K-aberrant and FGFR1 amplified stage IV squamous cell lung cancers (SQCLCs)
    Meeting Abstract

    Paik, P. K.; Moreira, A. L.; Wang, L.; Rekhtman, N.; Sima, C. S.; Won, H.; Ladanyi, M.; Berger, M. F.; Kris, M. G.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Treatment with therapies matched to oncogenic drivers improves survival in patients with lung cancers: Results from the Lung Cancer Mutation Consortium (LCMC)
    Meeting Abstract

    Kris, M. G.; Johnson, B.; Berry, L.; Kwiatkowski, D.; Iafrate, A. J.; Wistuba, I.; Varella-Garcia, M.; Franklin, W.; Aronson, S.; Su, P. F.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Results with dacomitinib (PF-00299804), an irreversible PAN-HER tyrosine kinase inhibitor, in a phase II cohort of patients with HER2-mutant or amplified lung cancers
    Meeting Abstract

    Kris, M. G.; Camidge, D. R.; Giaccone, G.; Hida, T.; O'Connell, J.; Taylor, I.; Zhang, H.; Gold-Berg, Z.; Jänne, P. A.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • FGFR1 amplification is associated with improved survival in patients with early-stage squamous cell carcinomas of the lung (SQCLC)
    Meeting Abstract

    Hellmann, M. D.; Wynne, M.; Wang, L.; Kris, M. G.; Sima, C. S.; Moreira, A. L.; Rekhtman, N.; Paik, P. K.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Tumor expression of TTF1 is associated with a doubling of overall survival in patients with advanced lung adenocarcinomas
    Meeting Abstract

    Hellmann, M. D.; Hilden, P. D.; Sima, C. S.; Kris, M. G.; Rekhtman, N.; Chaft, J. E.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • "Intention-to-treat" outcomes of sequential patients with stage IIIA lung adenocarcinomas treated with neoadjuvant chemotherapy with intent of surgical resection
    Meeting Abstract

    Hellmann, M. D.; Chaft, J. E.; Hilden, P. D.; Rusch, V. W.; Kris, M. G.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save